Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1508

Sort by

Sort Order Select

Journal Articles

Retinoids in hematology: a timely revival?

Marie-Claude Geoffroy, Cécile Esnault, Hugues de Thé

Blood (2021) 137 (18): 2429–2437.

https://doi.org/10.1182/blood.2020010100

Published: 2021

Journal Articles

A PML/RARα direct target atlas redefines transcriptional deregulation in acute promyelocytic leukemia

Yun Tan, Xiaoling Wang, Huan Song, Yi Zhang, Rongsheng Zhang, Shufen Li, Wen Jin, Saijuan Chen, Hai Fang, Zhu Chen, Kankan Wang

Blood (2021) 137 (11): 1503–1516.

https://doi.org/10.1182/blood.2020005698

Published: 2021

Includes: Supplemental data

Journal Articles

Acute myeloid leukemia with NPM1 and FLT3 ITD mimicking acute promyelocytic leukemia

Michael Pepper, Brent Tan

Blood (2020) 136 (12): 1467.

https://doi.org/10.1182/blood.2020007198

Published: 2020

Journal Articles

Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

Blood (2020) 136 (7): 823–830.

https://doi.org/10.1182/blood.2019004583

Published: 2020

Includes: Supplemental data

Journal Articles

Promyelocytic leukemia with basophil-like granules

Elisa Piva, Francesca Tosato

Blood (2020) 136 (3): 372.

https://doi.org/10.1182/blood.2020006060

Published: 2020

Journal Articles

Norsworthy KJ, Bird ST, Avagyan A, et al. Second cancers in adults with acute promyelocytic leukemia (APL) treated with or without arsenic trioxide (ATO): a SEER-Medicare analysis [abstract]. Blood. 2019;134(suppl 1). Abstract 3497.

Blood (2020) 135 (23): 2111.

https://doi.org/10.1182/blood.2020006455

Published: 2020

Journal Articles

Microgranular acute promyelocytic leukemia with expression of T-cell markers mimicking mixed-phenotype acute leukemia

Wei Liu, Jie Xu

Blood (2020) 135 (11): 880.

https://doi.org/10.1182/blood.2019004434

Published: 2020

Journal Articles

Integrated Transcriptomic and Genomic Sequencing Identifies Prognostic Constellations of Driver Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Ilaria Iacobucci, PhD, Manja Meggendorfer, PhD, Niroshan Nadarajah, Stanley Pounds, PhD, Lei Shi, PhD, Chunxu Qu, PhD, Constance Baer, PhD, Claudia Haferlach, MD, Wolfgang Kern, MD, Charles G. Mullighan, MBBS, MD, Torsten Haferlach, MD

Blood (2019) 134 (Supplement_2): LBA-4.

https://doi.org/10.1182/blood-2019-132746

Published: 2019

Journal Articles

Interim Results of a First in Man Study with the Fc-Optimized FLT3 Antibody Flysyn for Treatment of Acute Myeloid Leukemia with Minimal Residual Disease

Sabine Kayser, MD, Jonas S. Heitmann, MD, Daniela Dörfel, MD, Felicitas Thol, MD, Michael Heuser, MD, Melanie Märklin, PhD, Carsten Müller-Tidow, MD, Martin Steiner, Ludger Grosse-Hovest, Gundram Jung, MD, Richard F. Schlenk, MD, Helmut R. Salih, MD

Blood (2019) 134 (Supplement_1): 3928.

https://doi.org/10.1182/blood-2019-125327

Published: 2019

Journal Articles

First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia

Scott R. Solomon, MD, Aziz Nazha, MD, Stephen A. Strickland, MD, Roland B. Walter, MD PhD MS, Ilaria Valimberti, Alessia Tagliavini, Paolo Mazzei, Caterina Fiesoli, Simona Scartoni, Daniela Bellarosa, Monica Binaschi, PhD, Pawel Chrom, MD PhD, Simone Baldini, MD, Krzysztof Brzózka, PhD, Angela Capriati, Andrea Pellacani, PhD MD, Farhad Ravandi, MD

Blood (2019) 134 (Supplement_1): 3920.

https://doi.org/10.1182/blood-2019-125878

Published: 2019

Journal Articles

Efficacy and Safety of Daily All-Trans Retinoic Acid Monotherapy As Maintenance Therapy for Acute Promyelocytic Leukemia

Yoo Jin Lee, MD PhD, Seo-Yeon Ahn, MD, Jae-Cheol Jo, MD PhD, Yunsuk Choi, MD, Ji Hyun Lee, MD PhD

Blood (2019) 134 (Supplement_1): 3898.

https://doi.org/10.1182/blood-2019-125671

Published: 2019

Journal Articles

A Phase 1/2 Study of Quizartinib (Q) in Combination with Re-Induction Chemotherapy and As Single-Agent Continuation Therapy in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

C. Michel Zwaan, MD PhD, Edward Anders Kolb, MD, Derek E. Mires, PharmD, Michele Vigliotti, PharmD, Jingdong Xie, PhD, Pamela Downs, BS, Arthur P DeCillis, MD MS, Cara A Rabik, MD PhD, Todd M Cooper, DO

Blood (2019) 134 (Supplement_1): 3937.

https://doi.org/10.1182/blood-2019-121736

Published: 2019

Journal Articles

Meds433, a New Dihydroorotate Dehydrogenase Inhibitor, Induces Apoptosis and Differentiation in Acute Myeloid Leukemia

Valentina Gaidano, MD, Paola Circosta, PhD, Alessandro Cignetti, MD PhD, Mohammad Houshmand, Nicoletta Vitale, PhD, Stefano Sainas, PhD, Agnese Pippione, PhD, Manuela Marraudino, PhD, Brigitta Bonaldo, MD, Marta Giorgis, PhD, Donatella Boschi, PhD, Marco Lucio Lolli, PhD, Giuseppe Saglio, MD

Blood (2019) 134 (Supplement_1): 3942.

https://doi.org/10.1182/blood-2019-128085

Published: 2019

Journal Articles

Oral Arsenic Trioxide in Front Line Therapy for Acute Promyelocytic Leukemia. A Prospective Costa Rican Study

Mariela Rodriguez, MD, Ronald Rojas, Alejandra Vargas, MD, Miguel Angel Rodriguez, MD, Claudia Garcia, MD, Juliana Esquivel, MD, Jose Gerardo Rojas, MD, Willem Bujan Boza, MD

Blood (2019) 134 (Supplement_1): 3838.

https://doi.org/10.1182/blood-2019-122627

Published: 2019

Journal Articles

A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Courtney D. DiNardo, MDMSc, Rebecca Olin, MDMS, Jo Ishizawa, MD PhD, Hiroyuki Sumi, PhD, Jingdong Xie, PhD, Kazunobu Kato, MD PhD, Prasanna Kumar, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3932.

https://doi.org/10.1182/blood-2019-122241

Published: 2019

Journal Articles

Evaluating the Utilization of All- T rans Retinoic Acid and Arsenic Trioxide during Consolidation Therapy for Patients Receiving Treatment for Acute Promyelocytic Leukemia

Laura A Bowers, PharmD, Maho Hibino, PharmD, Rebecca Garcia Hunt, PharmD, Leslie Renee Ellis, MD, Rupali Bhave, MD, Dianna S. Howard, MD, Susan Lyerly, P.A.-C., Sarah Dralle, NP, Megan Manuel, NP, Timothy S. Pardee, MD PhD, Bayard L Powell, MD

Blood (2019) 134 (Supplement_1): 3901.

https://doi.org/10.1182/blood-2019-131817

Published: 2019

Journal Articles

Phase II Study of Midostaurin + Chemotherapy in Pediatric Patients with Untreated, Newly Diagnosed, FLT3 -Mutated Acute Myeloid Leukemia (AML)

Dirk Reinhardt, MD, Christian Michel Zwaan, Albert Hoenekopp, Julie Niolat, Sophie Ifrah, Florence Noel-Baron, Franco Locatelli, MD

Blood (2019) 134 (Supplement_1): 3835.

https://doi.org/10.1182/blood-2019-128043

Published: 2019

Journal Articles

A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)

Guru Subramanian Guru Guru Murthy, MBBS, Scott H. Kaufmann, MD PhD, Aniko Szabo, PhD, Arielle Baim, Ashish Anshu, Alexander Hinman, Laura C. Michaelis, MD, Sameem Abedin, MD, Karen-Sue B. Carlson, MD PhD, Lyndsey Runaas, MD, Ehab L. Atallah, MD

Blood (2019) 134 (Supplement_1): 3837.

https://doi.org/10.1182/blood-2019-131728

Published: 2019

Journal Articles

Treatment of Elderly Patients with Acute Promyelocytic Leukemia: A Real Life Experience of the "Rete Ematologica Lombarda"

Valentina Mancini, MD, Erika Borlenghi, MD, Livia Leuzzi, MD, Claudia Basilico, MD, Massimo Bernardi, MD, Patrizia Zappasodi, MD, Monica Fumagalli, MD, Elisabetta Todisco, MD PhD, Chiara Cattaneo, MD, Federico Lussana, MD, Giambattista Bertani, MD, Erika Ravelli, MD, Nicola Fracchiolla, Mauro Turrini, Giuseppe Rossi, Silvia Cantoni, Roberto Cairoli, MD

Blood (2019) 134 (Supplement_1): 3862.

https://doi.org/10.1182/blood-2019-130089

Published: 2019

Journal Articles

Acute Promyelocytic Leukemia (APL) in Very Elderly Patients: Real-Life behind Protocols

Serena Rosati, MD, Massimo Breccia, MD, Carmelo Gurnari, MD, Ida Carmosino, Emilia Scalzulli, MD, Enrico Montefusco, Salvatore Perrone, MD, Ombretta Annibali, Vincenza Martini, MD, Giulio Trapè, Malgorzata Monika Trawinska, MD, Clara Minotti, MD, Giuseppe Cimino, MD, Agostino Tafuri, MD, Giuseppe Avvisati, MD, Maria Teresa Voso, MD, Robin Foà, MD, Roberto Latagliata

Blood (2019) 134 (Supplement_1): 3845.

https://doi.org/10.1182/blood-2019-129216

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Retinoids in hematology: a timely revival?

A PML/RARα direct target atlas redefines transcriptional deregulation in acute promyelocytic leukemia

Acute myeloid leukemia with NPM1 and FLT3 ITD mimicking acute promyelocytic leukemia

Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

Promyelocytic leukemia with basophil-like granules

Norsworthy KJ, Bird ST, Avagyan A, et al. Second cancers in adults with acute promyelocytic leukemia (APL) treated with or without arsenic trioxide (ATO): a SEER-Medicare analysis [abstract]. Blood. 2019;134(suppl 1). Abstract 3497.

Microgranular acute promyelocytic leukemia with expression of T-cell markers mimicking mixed-phenotype acute leukemia

Integrated Transcriptomic and Genomic Sequencing Identifies Prognostic Constellations of Driver Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Interim Results of a First in Man Study with the Fc-Optimized FLT3 Antibody Flysyn for Treatment of Acute Myeloid Leukemia with Minimal Residual Disease

First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia

Efficacy and Safety of Daily All-Trans Retinoic Acid Monotherapy As Maintenance Therapy for Acute Promyelocytic Leukemia

A Phase 1/2 Study of Quizartinib (Q) in Combination with Re-Induction Chemotherapy and As Single-Agent Continuation Therapy in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

Meds433, a New Dihydroorotate Dehydrogenase Inhibitor, Induces Apoptosis and Differentiation in Acute Myeloid Leukemia

Oral Arsenic Trioxide in Front Line Therapy for Acute Promyelocytic Leukemia. A Prospective Costa Rican Study

A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Evaluating the Utilization of All- T rans Retinoic Acid and Arsenic Trioxide during Consolidation Therapy for Patients Receiving Treatment for Acute Promyelocytic Leukemia

Phase II Study of Midostaurin + Chemotherapy in Pediatric Patients with Untreated, Newly Diagnosed, FLT3 -Mutated Acute Myeloid Leukemia (AML)

A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)

Treatment of Elderly Patients with Acute Promyelocytic Leukemia: A Real Life Experience of the "Rete Ematologica Lombarda"

Acute Promyelocytic Leukemia (APL) in Very Elderly Patients: Real-Life behind Protocols

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only